<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824392</url>
  </required_header>
  <id_info>
    <org_study_id>ATYR1923-C-002</org_study_id>
    <nct_id>NCT03824392</nct_id>
  </id_info>
  <brief_title>Study of Intravenous ATYR1923 for Pulmonary Sarcoidosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>aTyr Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Sarcoidosis Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>aTyr Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, study will evaluate the safety,&#xD;
      tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple&#xD;
      ascending doses of IV ATYR1923 in patients with pulmonary sarcoidosis undergoing a&#xD;
      protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3&#xD;
      staggered multiple dose cohorts. Each eligible participant will participate in only one&#xD;
      cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to&#xD;
      ATYR1923 (N=8) or placebo (N=4).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2019</start_date>
  <completion_date type="Actual">June 29, 2021</completion_date>
  <primary_completion_date type="Actual">June 29, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>36 participants with pulmonary sarcoidosis will be randomized into one of 3 sequential cohorts, each comprising 12 participants allocated 2:1 to ATYR1923:Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events and serious adverse events</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cumulative steroid dose administered over study period</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve and maintain the targeted tapered dose of prednisone 5 mg/kg day</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure response analysis comparing steroid dose area under the curve (AUC) with ATYR1923 PK parameters</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of positive anti-drug-antibodies (anti-ATYR1923)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of anti-Jo-1 antibodies</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATYR1923 1.0 mg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATYR1923 3.0 mg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATYR1923 5.0 mg/kg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATYR1923 1.0 mg/kg or placebo</intervention_name>
    <description>ATYR1923 participants to receive ATYR1923 1.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATYR1923 3.0 mg/kg or placebo</intervention_name>
    <description>ATYR1923 participants to receive ATYR1923 3.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATYR1923 5.0 mg/kg or placebo</intervention_name>
    <description>ATYR1923 participants to receive ATYR1923 5.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of pulmonary sarcoidosis for ≥6 months (cutaneous and ocular involvement&#xD;
             allowed), defined as:&#xD;
&#xD;
               -  Histologically proven diagnosis of sarcoidosis by bronchoscopy, biopsy (any&#xD;
                  organ) or bronchioalveolar lavage&#xD;
&#xD;
               -  Parenchymal lung involvement by historical radiological evidence&#xD;
&#xD;
          -  Must have symptomatic and/or active pulmonary sarcoidosis as evidence by:&#xD;
&#xD;
               -  Modified Medical Research Council Dyspnea Scale grade of &gt;= 1; and&#xD;
&#xD;
               -  Forced vital capacity ≥50%; and&#xD;
&#xD;
          -  Receiving treatment with 10 to 25 mg/day of oral prednisone (or equivalent), at a&#xD;
             stable dose for ≥4 weeks prior to Day 1, and capable of undergoing the&#xD;
             protocol-specified steroid taper regimen.&#xD;
&#xD;
          -  Body weight ≥45 kg and &lt;160 kg.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current disease presentation consistent with Lofgren's syndrome.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to therapeutic proteins or known&#xD;
             sensitivity to ATYR1923 or to its inactive components (L-histidine, sodium chloride,&#xD;
             sucrose, L-methionine, and polysorbate-20).&#xD;
&#xD;
          -  Treatment with biological immunomodulators such as tumor necrosis factor-alpha&#xD;
             inhibitors.&#xD;
&#xD;
          -  Current evidence of clinically significant cardiovascular, hepatic, renal,&#xD;
             hematological, metabolic, or gastrointestinal disease, or has a condition that&#xD;
             requires other treatment.&#xD;
&#xD;
          -  Clinically significant pulmonary hypertension requiring vasodilator treatment.&#xD;
&#xD;
          -  Any history of tuberculosis or evidence of active systemic non-tuberculosis fungal or&#xD;
             mycobacterial infection within 1 year of Screening.&#xD;
&#xD;
          -  History of clinically significant cardiac, neurological, gastrointestinal, and/or&#xD;
             renal manifestations of their sarcoidosis.&#xD;
&#xD;
          -  Any condition that necessitated hospitalization within the 3 months prior to Day 1 or&#xD;
             is likely to require so during the study.&#xD;
&#xD;
          -  Participation in another clinical study of an investigational agent or device within 3&#xD;
             months (small molecules) / 6 months (biologics) or 5 half-lives (if known) of the&#xD;
             agent, whichever is longer.&#xD;
&#xD;
          -  History of or positive results of screening for hepatitis B, hepatitis C or human&#xD;
             immunodeficiency virus.&#xD;
&#xD;
          -  Is an active, heavy smoker of tobacco/nicotine-containing products (defined as &gt;20&#xD;
             cigarettes/day or e-cigarette equivalent).&#xD;
&#xD;
          -  Active substance abuse or history of substance abuse within the 12 months prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Patient has received a live vaccination within 8 weeks before Day 1 or inoculation&#xD;
             with a live vaccine is planned during study participation.&#xD;
&#xD;
          -  Positive for Jo-1 antibodies (Ab) at Screening, or past history of Jo-1 Ab positivity.&#xD;
&#xD;
          -  Significant and/or acute illness within 5 days prior to drug administration that may&#xD;
             impact safety assessments, in the opinion of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gennyne Walker</last_name>
    <role>Study Director</role>
    <affiliation>aTyr Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>aTyr Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>aTyr Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>aTyr Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>92425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Center</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Sarcoidosis</keyword>
  <keyword>Resokine</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Granulomas</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Interstitial Lung Disease</keyword>
  <keyword>Neuropilin-2</keyword>
  <keyword>Steroids</keyword>
  <keyword>Oral corticosteroids</keyword>
  <keyword>Immunomodulatory</keyword>
  <keyword>tRNA Synthetase</keyword>
  <keyword>ATYR1923</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

